Drug Database
DA

darbepoetin

✓ Approved

PanPharmaceuticals USA · EPOR · 重组蛋白

什么是 darbepoetin?

darbepoetin 是一种重组蛋白,由PanPharmaceuticals USA研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

公司PanPharmaceuticals USA
药物类别重组蛋白
分子靶点EPOR
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

darbepoetin 作用于 1 个分子靶点:

EPORerythropoietin receptor (EPO-R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

darbepoetin 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

相关研究文献

PubMedActa medica portuguesa2026-11-17

Hyperhemolysis Syndrome in a Pediatric Patient with Sickle Cell Disease.

Grilo Sofia S, Castello-Branco Ribeiro Luísa L, Ventura Ana A, Mendes Maria Maria MM et al.

Hyperhemolysis syndrome is a rare delayed post-transfusion hemolytic reaction, characterized by the destruction of transfused and autologous red blood cells, that occurs mostly in patients with chronic hemolysis. In patients with sickle cell disease severe complications may develop, with an associated significant morbidity and mortality. We describe the case of a 17-year-old female patient with sickle cell disease with poor transfusional yield, associated with a high hemoglobin S percentage (92%) and significant hemolysis, that lead to a diagnosis of hyperhemolysis syndrome. A multidisciplinary management approach included limiting red blood cell transfusions, supportive care with darbepoetin, therapeutic plasma exchange, intravenous immunoglobulin, and steroids, which resulted in a favorable clinical response. This case aims to shed light on a rare entity to avoid additional transfusions, which can further exacerbate hemolysis, and to ensure an appropriate management of this potentially fatal condition.

PMID 43045065
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Comparing Erythropoietin, Darbepoetin and No Erythropoiesis-Stimulating Agent Treatment in Preventing Anemia of Prematurity: A Multi-Center Retrospective Study.

Gadassi Noa N, Goldstein Sivahn S, Wulkan Michal M, Grinblatt Eynit E et al.

Objectives: To compare the effects of two different erythropoiesis-stimulating agents [ESAs] and no treatment on the number of blood transfusions and hematocrit [Hct] level. Methods: A retrospective study. Kaplan Medical Center provided data on ESA-treated infants, comparing erythropoietin [EPO] given per protocol until 2018 and darbepoetin [DPO] given from 2018 onwards. Meir Medical Center's data formed the control group. Data regarding ESA treatment were extracted from a computerized prospective database. A comparison of Hct levels at birth, 14 days of age, 1 month and before discharge and number of blood transfusions received during hospitalization was performed. Mean and standard deviation or median and interquartile range were used for continuous variables and frequency tables for categorical variables. Results: In total, 248 premature infants born between 2016 and 2021 under 1250 g, who survived beyond two weeks of age, were included. No significant differences were found between the EPO and DPO groups in terms of number of blood transfusions or Hct values. The control group received more blood transfusions after two weeks of age [0.8 ± 1.5 vs. 0.5 ± 1.2, p-value = 0.02]. In the treated group, higher Hct values were observed at one month of age [29.9 ± 4.2 vs. 37.9 ± 5.3, p-value < 0.01] and at discharge [29.7 ± 3.8 vs. 34.1 ± 4.6, p-value < 0.01] compared to the control group. Conclusions: ESA treatment was associated with higher hematocrit levels, and no significant differences in efficacy were found between EPO and DPO.

PMID 43030394
阅读全文 →
PubMedNeonatology2026-11-13

Relationship between Darbepoetin and Intermittent Hypoxemia in Preterm Infants.

Di Fiore Juliann M JM, Hibbs Anna Maria AM, Minich Nori Mercuri NM, Ambalavanan Namasivayam N et al.

In the Darbepoetin to Improve Red Cell Mass and Neuroprotection in Preterm Infants Trial (Darbe; NCT03169881), infants <29wks gestation receiving darbepoetin were less likely to develop bronchopulmonary dysplasia (BPD) and had higher hematocrit and red blood cell counts (RBC) suggesting that darbepoetin may augment tissue oxygen delivery and thereby improve respiratory outcomes. Intermittent hypoxemia (IH) is associated with an increased risk of BPD, and it is possible that darbepoetin reduces BPD by attenuating IH. A subcohort of 94 infants enrolled in Darbe were retrospectively analyzed. Number, duration, nadir and total time with IH <90% and <80% were identified through 42 days of age on continuous oxygen saturation recordings. Hematocrit and RBC counts were documented at days 14 and 42. Darbepoetin infants had a higher hematocrit at day 42 and there were fewer IH events <80% with a higher hematocrit (β=-1.51, 95% CI (-2.67, -0.36), p=0.03). However, the effect of darbepoetin supplementation on patterns of IH was limited to a significantly higher nadir (less severe) for IH <80% (β=-0.02, 95% CI (-0.04, 0), p=0.04). Darbepoetin increases hematocrit but only modestly improves oxygen stability in preterm infants.

PMID 43023688
阅读全文 →
PubMedNature communications2026-10-29

A human erythropoietin-albumin fusion protein tailored for enhanced plasma half-life and delivery across mucosal surfaces.

Anthi Aina Karen AK, Bejan Daniela D, Mester Simone S, Bethur Nijaguna N et al.

Erythropoietin (EPO) products stimulate production of erythrocytes in patients with anemia. The drugs are delivered intravenously or subcutaneously up to several times per week due to short plasma half-life. Improving the pharmacokinetic properties of EPO will allow less frequent administration, and thus impact therapeutic utility and patient compliance. In this study, we took advantage of an albumin variant (QMP) engineered for improved engagement of FcRn, a key regulator of the plasma half-life of albumin. After genetic coupling of EPO to QMP, the fusion protein shows favorable neonatal Fc receptor (FcRn) binding, and 5.2-fold prolonged plasma half-life in human FcRn expressing mice upon intravenous administration, when comparing with EPO fused to WT albumin, with a similar half-life obtained following subcutaneous administration. Importantly, both fusions bind the EPO receptor with binding kinetics equal to that of the product darbepoetin alfa. After intravenous administration, mice receiving darbepoetin alfa experiences a faster drop in EPO levels compared to those given EPO-QMP, and moreover, we measure a prolonged increase in erythrocytes with EPO-QMP. Furthermore, intranasal administration results in 5-fold higher circulating amounts of EPO-QMP and a prolonged increase in erythrocytes compared to darbepoetin alfa. Thus, long-acting EPO-QMP could be an attractive design to explore for both invasive and non-invasive delivery to patients with anemia.

PMID 42951888
阅读全文 →
PubMedVeterinary sciences2026-10-27

Hematologic Responses to Molidustat in Cats with Anemia of Heterogeneous Etiology: A Retrospective Descriptive Study.

Lee Gippeum G, Lee Jeongmin J, Song Kun-Ho KH

Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for nonregenerative anemia associated with chronic kidney disease (CKD) in cats but is also used for anemia of other causes. This retrospective, single-center study described the hematologic response to molidustat in 39 cats with anemia of heterogeneous etiology and identified factors that complicate attribution of improvement to the drug. Response was defined as a hematocrit (HCT) increase of ≥4 percentage points from baseline at the complete blood count closest to day 28 (days 14-45), without transfusion to treat anemia. Molidustat was used outside the approved indication in 33 cats (84.6%). Seventeen cats (43.6%) had a response-window measurement; they had a longer treatment span and differed in etiology and concurrent treatment from non-evaluable cats. Among these 17 cats, 12 (70.6%; 95% CI 46.9-86.7%) met the response criterion; sensitivity analyses specified before formal analysis gave 70.6-75.0% and post hoc attribution analyses 29.4-50.0%. In 7 of the 12 responders, darbepoetin or transfusion preceded the qualifying measurement, or it was obtained more than 7 days after the last dose. These data describe clinical use but do not establish effectiveness outside CKD-associated anemia.

PMID 42944170
阅读全文 →
PubMedDrug testing and analysis2026-10-22

Doping Control Analysis of Darbepoetin Alfa Biosimilars in Human Urine, Serum, Plasma, and Dried Blood Spots.

Akiyama Kentaro K, Sakurai Hikaru H, Sato Mitsuhiko M, Momobayashi Atsushi A et al.

Following the patent expiration of the originator darbepoetin alfa, three biosimilar products have been marketed in Japan; however, their detectability by current anti-doping methods has not yet been verified. The present study assessed whether these biosimilars can be detected in human urine, serum, plasma, and dried blood spots (DBS) using the established initial testing procedure and confirmation analysis for erythropoietin-receptor agonists. The originator product and three biosimilars (5 μg, i.v.) were administered to healthy male volunteers. Samples collected up to 72 h postdose were subjected to immunopurification followed by sodium N-lauroyl sarcosinate polyacrylamide-gel electrophoresis (SAR-PAGE) as the initial testing procedure. Confirmation was performed by SAR-PAGE with double blotting for serum and plasma. DBS and urine samples were confirmed by SAR-PAGE using an alternative antibody, and urine samples were further examined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). SAR-PAGE analysis of the pharmaceutical preparations revealed product-specific electrophoretic profiles: two biosimilars migrated slightly above one originator product as diffused smears, whereas the third produced a sharp band comparable to that of another originator product. Similar profiles were observed in postdose samples from all biological matrices, and all biosimilars remained detectable in urine, serum, plasma, and DBS for at least 72 h. Although some biosimilars showed distinct SAR-PAGE banding patterns, product attribution remained limited. LC-MS/MS confirmed administered darbepoetin alfa in the 24 h urine samples but did not detect analyte in lower concentration samples, indicating that its performance was concentration-dependent. Accordingly, SAR-PAGE should incorporate reference standards beyond the originator product, particularly those with different band morphologies.

PMID 42902912
阅读全文 →

注册免费账户还可查看另外 1437 篇文献

免费注册查看全部文献 →

了解更多darbepoetin